サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1136915

ワクチンデリバリーデバイスの世界市場-2022-2029

Global Vaccine Delivery Devices Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ワクチンデリバリーデバイスの世界市場-2022-2029
出版日: 2022年10月13日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

ワクチンデリバリーデバイス市場の成長は、COVID-19などのさまざまな感染症の流行、高齢者人口の増加、および研究開発活動によってもたらされます。

一般市民の予防接種に対する意識の高まりが市場成長の原動力になると予想される

COVID-19などの疾病の流行が増加していることが、予測期間中に市場を押し上げると予想される全国予防接種啓発月間（NIAM）は、8月の月に祝われます。NIAM 2021のデータによると、COVID-19の症例は全国的に増加しているため、ワクチン接種を受けることが必要です。NIAMでは、全国予防接種啓発を奨励し、COVIDをはじめ、ジフテリア、はしか、おたふくかぜ、ポリオ、風疹、破傷風などの病気に対する予防接種を増やすための戦略を議論しています。この戦略には、ワクチン接種へのためらいをなくすために、十分な治療を受けていない地域社会への働きかけ、小児患者の年次検診の奨励、予防接種スケジュールの維持のための提唱などが含まれています。

また、主なプレイヤーは買収や製品開発などの市場戦略を採用しています。例えば、2020年4月、ニュージーランド・ファーマは、米国の医療関連企業であるバレリタス・ホールディングスを2,300万米ドルで買収しました。また、2021年11月、ゲレスハイマーは、新しい自動注射器についてMidas Pharmaと提携しました。この提携には、新世代の自動注射器の開発およびマーケティングが含まれています。

さらに、2021年8月、インドのワクチン開発者血清研究所は、医薬品包装会社Schott Kaishaの株式50％を非公開の金額で取得しました。ショット社はドイツに本拠を置くプレーヤーで、バイアル、シリンジ、カートリッジを製造しています。

ワクチンデリバリーデバイスの不足が市場成長の妨げに

しかし、いくつかの病気に対する高度な治療により、多くの人々がヘルスケアを受けることができません。例えば、バイオジェン社が販売し、脊髄性筋萎縮症の治療に使用されているスピンラザのコストは、患者1人当たり初年度約75万米ドル、年間37万5,000米ドルとなっています。これらの要因は、市場の成長にマイナスの影響を与えます。

COVID-19の影響分析

COVID-19の登場は、世界のワクチンデリバリーデバイス市場にかなりの影響を与えました。

2021年11月のPATHデータレポートによると、2021年末から2022年半ばにかけて40億以上と予想されるCOVID-19ワクチン用注射器の需要急増は、ワクチンCOVAX、政府からの多額の寄付、二国間取引を通じて来る各国へのCOVID-19ワクチン用量納入の推定増加によるものです。PATHのモデリングでは、世界の需給データに基づいて、12億本のADシリンジの世界のギャップを推定しています。例えば、2021年11月、新PATHモデリングは、COVID-19ワクチン送達のための12億の自動無効化シリンジ安全注入装置の世界市場の供給ギャップを予想しています。このギャップは、世界各国でのワクチンのタイムリーな配送を危うくする停止となる危険性があります。

一方、輸出規制、出荷の遅れ、新規製造ラインが世界保健機関のガイドラインに適合しない、あるいは計画された製造拡張の完了が遅れるなど、注射器供給に対する課題があれば、この期間中に累積ギャップが20億以上に拡大する可能性があります。また、ブースター用量は、市場にさらなる需要圧力を生じさせる可能性があります。

世界のワクチンデリバリーデバイス市場レポートでは、約65以上の市場データ表、65以上の図表、200以上のページ（概算）にアクセスできるようになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 技術的進歩
      • ワクチンデリバリーデバイスの需要増加
    • 抑制要因
      • ワクチンデリバリーデバイスの高コスト
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 法規制の分析
  • プライシング分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品タイプ別

  • ジェットインジェクター
  • シリンジ
  • マイクロニードル
  • その他

第8章 投与経路別

  • 皮下接種
  • 筋肉内接種
  • 皮内接種
  • ニードルフリー製剤
  • その他

第9章 エンドユーザー別

  • 病院
  • コミュニティセンター
  • 研究・学術機関
  • 外来手術センター
  • その他

第10章 流通チャネル別

  • 病院
  • オンライン薬局
  • 小売薬局
  • 病院内薬局
  • 予防接種センター

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第13章 企業プロファイル

  • 3M
    • 企業概要
    • 治療タイプのポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Becton Dickinson & Company
  • Inovio Pharmaceutical Inc.
  • PharmaJet
  • Vaxxas
  • Gerresheimer AG
  • SCHOTT AG
  • Corium International, Inc.
  • Intravaac

第14章 ワクチンデリバリーデバイスの世界市場-DataM

目次
Product Code: DMMD819

Market Overview

Vaccine Delivery Devices Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.2% during the forecast period (2022-2029).

The vaccine delivery device is used for proper vaccine delivery to ensure successful vaccination. Mainly, most vaccines are administered via the subcutaneous (SC) or intramuscular (IM) routes.

Market Dynamics

The vaccine delivery devices market growth is driven by the rise in the prevalence of different infectious diseases, such as COVID-19, an increase in the geriatric population, and research and development activities.

The rising awareness of immunizations in public is expected to drive the market growth

The increasing prevalence of diseases, such as COVID-19, is expected to boost the market over the forecast period. National Immunization Awareness Month (NIAM) is celebrated in August month. As per NIAM 2021 data, COVID-19 cases are increasing nationwide, so it is necessary to take the vaccination. NIAM encourages National Immunization Awareness and discusses strategies for increasing immunizations for COVID and other diseases such as diphtheria, measles, mumps, polio, rubella, and tetanus, among others diseases. The strategies include local outreach to underreserved communities to reduce vaccine hesitancy, encouraging annual checkups of pediatric patients, and advocating to keep up the immunization schedule.

In addition, the key players are adopting the market strategies such as acquisition and product development. For instance, in April 2020, Zealand Pharma acquired Valeritas Holdings, a U.S.-based medical company, for USD 23 Mn. Also, in November 2021, Gerresheimar partnered with Midas Pharma for a new auto-injector. The partnership contains the development and marketing of a new-generation auto-injector.

Furthermore, in August 2021, the Vaccine developer Serum Institute of India acquired a 50% stake in pharma packaging company Schott Kaisha for an amount that was not disclosed. Schott AG is a Germany-based player that manufactures vials, syringes, and cartridges.

The shortage of vaccine delivery devices will hamper the growth of the market

However, many people cannot afford healthcare due to advanced treatment for several diseases. For instance, the cost of Spinraza, marketed by Biogen and used for the treatment of spinal muscular atrophy, is around US$ 750,000 per patient in the first year and US$ 375,000 annually. These factors negatively affecting on market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global vaccine delivery devices market.

According to November 2021 PATH data report, the expected spike in demand for syringes for COVID-19 vaccines, anticipated to total more than 4 billion from the year-end of 2021 to mid-2022, is due to the estimated increase in COVID-19 vaccine dose deliveries to countries coming through vaccine COVAX, large donations from governments, and bilateral deals. The PATH modeling estimates a global gap of 1.2 billion AD syringes based on global supply and demand data. For instance, in November 2021, New PATH modeling anticipates a global market supply gap of 1.2 billion auto-disable syringe safe-injection devices for COVID-19 vaccine delivery. This gap risks becoming a stoppage that could risk the timely delivery of vaccines in countries worldwide.

On the other hand, challenges to syringe supply, such as export restrictions, shipping delays, new manufacturing lines failing to receive World Health Organization guidelines, or delays in completing planned manufacturing expansions, could broaden the cumulative gap to more than 2 billion during this period. Also, Booster doses could create further demand pressures on the market.

Segment Analysis

The microneedles segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The microneedles segment is expected to boost the market throughout the forecast. As per the article published in Pharmaceutics 2022, the maintenance of the vaccine potency, transportation, and needle waste generation have become major issues. Moreover, needle phobia and vaccine hesitancy are hurdles to successful mass vaccination. Dissolvable microneedles for vaccination could act as a major paradigm shift in attaining the desired goal of vaccinating billions in the shortest time possible.

Using dissolvable microneedle patches would improve the dosing accuracy, ensuring the precise delivery of the vaccines. Using biodegradable microneedles for transdermal immunization is a fast-developing topic of study and application. Microneedles have several benefits over traditional immunization, such as intramuscular and subcutaneous injections, aside from the fact that they are painless, slowing the release of vaccination antigens. Vaccine components in microneedles may be in solution or suspension, coated in nano or microparticles, or based on nucleic acids. Due to the combined advantages of particulate vaccinations and pain-free vaccination, the use of microneedles to administer particle-based immunizations is growing rapidly.

In addition, in May 2020, Altaris Capital Partners acquired Kindeva Drug Delivery for $650 million. With the help of the expertise of 3M and the Kindeva team, Altaris able to develop innovative drug delivery technologies in the healthcare sector.

Geographical Analysis

North America region holds the largest market share of the global vaccine delivery devices market

North America dominates the market for vaccine delivery devices and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, rising chronic and infectious diseases, and launching new products. The presence of market players and government initiatives for public health drives the market. For instance, the United States government has ordered 286 million needles and syringes from B.D., with 256 million to be given by January 2021. These devices will help to deliver a safe, effective COVID-19 vaccine to millions of Americans as soon as one is available. In July 2020, ASPR's Biomedical Advanced Research and Development Authority (BARDA) invested approximately $42 million into a $70 million capital project to further expand B.D.'s operations and manufacturing lines in Holdrege, Neb. The expansion builds on the company's deep commitment and legacy in supporting U.S. vaccination efforts through the domestic manufacturing of needles and syringes.

Competitive Landscape

The vaccine delivery devices market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are 3M, Becton Dickinson & Company, Inovio Pharmaceutical Inc., PharmaJet, Vaxxas, Gerresheimer AG, SCHOTT AG, Corium International, Inc. and Intravaac, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global vaccine delivery devices market.

For instance,

  • In 2021, Rockwell industries launched the world's hybrid freezer, which is used to store the COVID-19 vaccine.
  • In 2021, Becton and Dickison launched a needles & syringes multi-drug delivery facility device that helps administer COVID-19 vaccines.

Becton Dickinson & Company

Overview:

Becton Dickinson & Company is an American multinational medical technology company headquartered in the United States that provides advancing health solutions for patient safety and clinical outcomes. It offers the vaccine syringe and other drug delivery systems in the market.

Product Portfolio:

BD Hypak: It is used for vaccines glass pre-fillable syringe system, a reliable glass pre-fillable syringe system specifically optimized for vaccinations. The system fulfills customer needs for better processability of the syringe during filling and packaging operations.

The global vaccine delivery devices market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
      • 4.1.1.2. Rising demand for vaccine delivery devices
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of Vaccine Delivery Devices
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Jet Injectors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Syringes
  • 7.4. Microneedles
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Subcutaneous Vaccination*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Intramuscular Vaccination
  • 8.4. Intra Dermal Vaccination
  • 8.5. Needle Free Delivery
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Community Centers
  • 9.4. Research and Academic Institutes
  • 9.5. Ambulatory Surgical Center
  • 9.6. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies
  • 10.5. Hospital Pharmacies
  • 10.6. Vaccination Centers

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. 3M*
    • 13.1.1. Company Overview
    • 13.1.2. Treatment type Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Becton Dickinson & Company
  • 13.3. Inovio Pharmaceutical Inc.
  • 13.4. PharmaJet
  • 13.5. Vaxxas
  • 13.6. Gerresheimer AG
  • 13.7. SCHOTT AG
  • 13.8. Corium International, Inc.
  • 13.9. Intravaac

LIST NOT EXHAUSTIVE

14. Global Vaccine Delivery Devices market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us